Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

279.38 -10.73 (-3.70%)
Streaming Delayed Price Updated: 3:27 PM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
3 Market-Beating Stocks with Solid Fundamentals
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
1 Healthcare Stock with Solid Fundamentals and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
This Kraft Heinz Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Via Benzinga
Insights Ahead: Medpace Hldgs's Quarterly Earnings
Via Benzinga
Exploring Medpace Hldgs's Earnings Expectations
Via Benzinga
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
Earnings Preview For Medpace Hldgs
Via Benzinga
Examining the Future: Medpace Hldgs's Earnings Outlook
Via Benzinga
A Look at Medpace Hldgs's Upcoming Earnings Report
Via Benzinga
2 Reasons to Watch MEDP and 1 to Stay Cautious
Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period. 
Via StockStory
Topics Stocks
Exposures US Equities
Why Medpace (MEDP) Shares Are Trading Lower Today
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and... 
Via StockStory
Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Medpace Stock Falls On Q4 Earnings: The Details
Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report. 
Via Benzinga
Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops
Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s... 
Via StockStory
Earnings Scheduled For February 10, 2025
Via Benzinga
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect. 
Via StockStory
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This McDonald's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Why Is Medpace Stock Diving On Tuesday?
Medpace Holdings reports Q3 results with revenue of $533.3M, below consensus. Backlog and EBITDA increased. Medspace lowered its FY24 revenue forecast. 
Via Benzinga
How Medpace Just Blew Up Expectations For Double-Digit Sales Growth In 2025
The contract research organization missed bookings expectations, but didn't offer into any insight into the impact for 2025. 
Via Investor's Business Daily
Sherwin-Williams Posts Weak Results, Joins Logitech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.